Table 2.
Secondary outcomes
| Characteristic | IV Ig, N = 21 | Oral antibiotics, N = 42 |
|---|---|---|
| Number of clinically documented infections, n | 39 | 56 |
| Number of participants with clinically documented infections, n (%) | ||
| 0 infections | 3 (14) | 18 (43) |
| 1 infection | 5 (24) | 12 (29) |
| 2 infections | 8 (38) | 2 (5) |
| ≥ 3 infections | 5 (24) | 5 (24) |
| Number of microbiologically documented infections, n | 11 | 16 |
| Number of participants with microbiologically documented infection, n (%) | ||
| 0 infections | 13 (62) | 34 (81) |
| 1 infection | 6 (29) | 2 (5) |
| 2 infections | 1 (5) | 5 (12) |
| ≥ 3 infections | 1 (5) | 1 (2) |
| Participants with resistant organism identified, n | ||
| Cotrimoxazole resistant | 1 | 0 |
| Extended-spectrum β-lactamases | 1 | 0 |
| Multidrug resistant | 0 | 3 |
| Number of deaths, n (%) | 2 (9.5) | 1 (2.4) |
| Number of infection deaths, n (%) | 1 (4.8) | 1 (2.4) |
| IgG (g/L), median (IQR) | 9.1 (7.4-11.1) | 4.2 (3.3-5.6) |
| Number of treatment-related AEs∗, n | ||
| Grade 1 | 3 | 5 |
| Grade 2 | 2 | 11 |
| Grade 3 | 4 | 4 |
| Duration of IV antibiotics (d), median (IQR) | 2.0 (2.0-2.0) | 3.0 (2.5-3.5) |
| Hospital duration (d), median (IQR) | 2.0 (1.0-4.5) | 2.0 (1.0-4.0) |
AEs, adverse events.
∗
No treatment-related grade 4 or 5 AEs reported.